Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionKoshinski Asset Management, Inc.
Latest Disclosed Ownership1,608 shares
Latest Disclosed Value $ 718,036
Koshinski Asset Management, Inc. reports 10.44% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 27, 2026 - Koshinski Asset Management, Inc. filed a 13F-HR form disclosing ownership of 1,608 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $718,036 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 3, 2026 disclosing 1,456 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 10.44% during the quarter. The current value of the position is $718,503 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-27 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,608 152 10.44 718 8.79 0.0447
2026-02-03 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,456 117 8.74 660 25.95 0.0425
2025-11-10 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,339 39 3.00 524 -9.34 0.0352
2025-07-29 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,300 2 0.15 579 -8.11 0.0437
2025-04-25 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,298 -59 -4.35 629 15.20 0.0534
2025-01-16 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,357 45 3.43 546 -10.49 0.0467
2024-10-10 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,312 -14 -1.06 610 -5.28 0.0528
2024-07-12 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,326 1,326 644 0.0597
2024-05-08 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -500 -100.00 0 -100.00
2024-01-29 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 500 -1,004 -66.76 203 -61.19 0.0309
2023-10-18 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,504 -56 -3.59 523 -4.56 0.0601
2023-07-28 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,560 71 4.77 549 16.84 0.0588
2023-04-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,489 10 0.68 469 9.84 0.0458
2023-01-24 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,479 14 0.96 427 0.0413
2022-10-20 2022-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,465 -122 -7.69 0 0.0506
2022-07-12 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,587 -220 -12.17 0 -100.00 0.0444
2022-04-20 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,807 -404 -18.27 472 -2.89 0.0387
2022-01-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,211 201 10.00 486 33.24 0.0392
2021-10-12 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,010 -449 -18.26 365 -26.61 0.0317
2021-07-26 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,459 -644 -20.75 496 -25.64 0.0624
2021-05-06 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,103 675 27.80 667 16.20 0.0707
2021-03-30 2020-12-31 13F/A-2 VERTEX PHARMACEUTICALS COM 92532F100 2,428 341 16.34 574 0.17 0.0727
2021-02-05 2020-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,973 -455 574 0.0727
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,087 -241 -10.35 573 -15.24 0.0770
2020-07-29 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,328 879 60.66 676 95.94 0.1096
2020-04-30 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,449 47 3.35 345 12.38 0.0725
2020-01-29 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,402 1,402 307 0.0528
2019-05-14 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -2,887 -100.00 0 -100.00
2019-02-08 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,887 -1,095 -27.50 478 -37.68 0.1175
2018-11-15 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,982 -4,050 -50.42 767 -43.81 0.1092
2018-08-13 2018-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 8,032 -40 -0.50 1,365 3.72 0.4167
2018-08-10 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,032 -40 572
2018-04-09 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,072 8,072 1,316 0.4089
2018-01-17 2017-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 0 -1,709 -100.00 0 -100.00
2018-01-17 2017-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,709 1,709 220 0.0802
2017-07-10 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,709 220
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.